AstraZeneca gets nod to launch cancer drug

AstraZeneca Pharma India has received approval from the Central Drugs Standard Control Organisation to import Durvalumab for sale and distribution. The drug, combined with chemotherapy, treats resectable non-small cell lung cancer without specific genetic mutations. Lung cancer remains a significant cause of mortality in India, highlighting the importance of this development.